If you read the article,

> [BioNTech] now expects to accrue 15.9 billion euros ($18.63 billion) in revenue from the vaccine this year <...> “Since BioNTech procures relatively few preliminary products from abroad, this is almost entirely domestic added value,” Dullien said. “So this has a direct impact on economic growth.”